Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AXSMBullishAnalyst Ratingnews

High materiality7/10

Axsome eyes SUMMIT Phase 3 initiation; overweight stance supports upside

Sep 21, 2026, 8:41 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive overweight rating with a high price target and near-term Phase 3 catalyst can drive short-term upside; biotech reactions to phase 3 catalysts have historically been favorable when validated by analysts.

AI summary

What happened, with direct paths to the underlying reporting

Axsome's SUMMIT Phase 3 for AXS-05 in smoking cessation kicked off Aug 31, per the article. Piper Sandler maintains an Overweight rating with a $258 price target, underscoring near-term upside despite a mixed market backdrop. The primary catalyst remains trial progress and analyst validation, potentially driving higher AXSM shares in months ahead.

Axsome started SUMMIT Phase 3 for AXS-05 (Aug 31).
Piper Sandler maintains Overweight on AXSM with $258 target.
Analyst David Amsellem notes AXSM ~24% upside with $258 target.
Market wrap shows mixed week; Nasdaq up, Dow down.
AXSM remains a high-beta biotech with near-term catalysts.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Axsome eyes SUMMIT Phase 3 initiation; overweight stance supports upside

Axsome shares fall after downbeat Q2 results; focus on pipeline viability

Axsome's Auvelity Expansion and Pipeline Growth Fuel Strong Upside

FDA Approves Axsome's Drug for Alzheimer's Agitation Treatment

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars